Menu Search
Equities

Journey Medical Corp

DERM:NAQ

Journey Medical Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)5.17
  • Today's Change0.05 / 0.98%
  • Shares traded6.21k
  • 1 Year change+108.47%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 17:17 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Journey Medical Corp grew revenues 7.48% from 73.67m to 79.18m while net income improved from a loss of 29.63m to a smaller loss of 3.85m.
Gross margin66.79%
Net profit margin1.09%
Operating margin2.73%
Return on assets1.25%
Return on equity14.92%
Return on investment5.17%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Journey Medical Corp fell by 4.56m. However, the company earned 5.24m from its operations for a Cash Flow Margin of 6.62%. In addition the company used 5.00m on investing activities and also paid 4.80m in financing cash flows.
Cash flow per share0.2064
Price/Cash flow per share18.39
Book value per share0.5642
Tangible book value per share-0.3678
More ▼

Balance sheet in USDView more

Journey Medical Corp has a Debt to Total Capital ratio of 66.82%, a lower figure than the previous year's 29,800.21%.
Current ratio1.36
Quick ratio1.08
Total debt/total equity2.01
Total debt/total capital0.6682
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 87.50%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		99.41
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.